Opinion 28 Jul 2025 How to solve the biotech bottleneck by funding ideas, not data Learn how Deep Science Ventures’ zero-data approach tackles biotech’s early funding challenges to speed innovation and reduce risk. July 28, 2025 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 18 Dec 2023 What to expect from biotech clinical trials in the coming year As cancer research has seen an increase in funding lately, here are some of the key clinical trends that you can expect in 2024. December 18, 2023 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 29 Nov 2023 Redefining drug development: the trailblazing evolution of the pharmaceutical industry Drug discovery and development is a long, costly, and high-risk process that takes over 10 to 15 years with an average cost of over $1 to $2 billion for each new drug to be approved for clinical use. For any pharmaceutical company or academic institution, it is a big achievement to advance a drug candidate […] November 29, 2023 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 1 Nov 2023 Could this be the start of a new era for PI3K drugs? There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs, a type of kinase inhibitor, after issues with the first generation from the class had brought up concerns. Phosphoinositide 3-kinases (PI3K) drugs work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that […] November 1, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 25 Oct 2023 Microbiome: are we ready for third generation live biotherapeutics? The microbiome sector has come a long way. From liquidizing fecal matter in a kitchen appliance for direct insertion into the intestine to the encapsulation of dried matter for oral delivery; and now to the creation of live biotherapeutics, single drug products of multiple bacterial strains. The application of microbiome therapeutics is also broadening – […] October 25, 2023 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 27 Sep 2023 Tackling the skilled labor shortage in biopharma manufacturing By Brandy Bullen, founder & CEO of Sequoia Consulting Group The biopharma manufacturing sector stands at a critical juncture as it grapples with an increasingly pronounced skilled labor shortage. In an era marked by rapid advancements in biotechnology and the growing demand for innovative therapies, the industry finds itself facing a pressing challenge – the […] September 27, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 20 Sep 2023 The next frontier in genomic technologies for rare diseases By Neil Ward, VP and General Manager at PacBio EMEA It’s been 40 years since the passage of the Orphan Drug Act, which catalyzed the development of hundreds of therapies for rare diseases, with more than half approved in the last decade. More recently in 2022, the U.K. government launched a Rare Diseases Action Plan […] September 20, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 11 Jul 2023 Unlocking the power of mRNA technology By Yochi Slonim, CEO and co-founder of Anima Biotech mRNA technology has gained widespread recognition due to its role in the development of vaccines, such as those used against COVID-19; however, the scope of mRNA extends far beyond vaccines, offering a range of applications for addressing different conditions. Vaccines represent a notable application of mRNA […] July 11, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 10 Jul 2023 Five innovations to take RNA vaccines to the next level By Venkata Indurthi, PhD, chief scientific officer, Aldevron During the COVID-19 pandemic, the world turned to a previously unused vaccine technology to rapidly develop desperately needed vaccines, providing immunity to millions worldwide. These new vaccines made use of the body’s natural translational machinery, which turns mRNA encoding the SARS-Cov2 spike protein into an antigen that […] July 10, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 30 Jun 2023 Virus tracking could be key to kidney transplant patients’ drug choices By Dr Gregor Bond More than 15,000 Europeans undergo kidney transplants on average each year, and while medical advances have helped many recipients enjoy healthy lives, the risks of organ rejection and infection remain huge challenges. With each transplant, success depends on using carefully balanced doses of immuno-suppressive drugs to reduce the risk of infection […] June 30, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 13 Jun 2023 How will European Commission proposals on data exclusivity and the bolar exemption affect pharma companies? By Andrew Sharples, co-head of EIP’s UK litigation team In April, the European Commission published proposed legislation (specifically a new Regulation and a new Directive) aimed at reforming EU legislation in relation to pharmaceuticals. These proposals, if adopted, will affect pharmaceutical regulation in several ways. In relation to IP specifically, they will affect the periods […] June 13, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Opinion 9 May 2023 Where is innovation needed in cell therapy? By Dr Ryan Roberts, cell processing lead at Cellular Origins Despite the rapidly emerging innovations in the field of cell and gene therapy, bottlenecks in cell therapy manufacturing processes are preventing these transformative medicines from reaching patients. There are several broad challenges to the scalability and affordability of cell therapies, including a reliance on manual […] May 9, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email